Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01924260 · ClinicalTrials.gov registry record · Phase 1

Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer

A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Stage IV Pancreatic Cancer, sponsored by Edward Kim.

Completed
Registry status
Phase 1
Development phase
26
Enrollment target
1
Study location

NCT01924260 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Stage IV Pancreatic Cancer that has completed, run by Edward Kim. The registered enrollment target is 26 participants, below the 501-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01924260, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Stage IV Pancreatic Cancer, has completed, sponsored by Edward Kim.

COMPLETED
Registry status
Phase 1
Development phase
26 participants
Enrollment target
1
Study location

Study Summary

This phase I trial studies the side effects and the best dose of alisertib when given together with gemcitabine hydrochloride in treating patients with solid tumors or pancreatic cancer that is metastatic or cannot be removed by surgery. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving alisertib with gemcitabine hydrochloride may be an effective treatment for solid tumors or pancreatic cancer.

Conditions Studied

Unspecified Adult Solid Tumor, Protocol Specific Stage IV Pancreatic Cancer Stage III Pancreatic Cancer Recurrent Pancreatic Cancer Acinar Cell Adenocarcinoma of the Pancreas Duct Cell Adenocarcinoma of the Pancreas

Interventions

  • DRUG gemcitabine
  • DRUG alisertib

Study Locations (1)

California

  • UC Davis Comprehensive Cancer Center - Sacramento

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2013-08-09
Est. Completion 2017-02-08
Phase Phase 1

Sponsor

Edward Kim

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01924260

The ClinicalTrials.gov registry entry for NCT01924260 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 501-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (95% lower). The listed sponsor is Edward Kim, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 2 interventions - of which gemcitabine is the first listed.

NCT01924260 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT01924260 about?

NCT01924260 is a clinical study titled "Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer". This phase I trial studies the side effects and the best dose of alisertib when given together with gemcitabine hydrochloride in treating patients with solid tumors or pancreatic cancer that is metastatic or cannot be removed by surgery. Alisertib may stop the growth of tumor cells by blocking some ...

What is the current status of trial NCT01924260?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2013-08-09. Estimated completion is 2017-02-08.

What conditions does trial NCT01924260 study?

This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific, Stage IV Pancreatic Cancer, Stage III Pancreatic Cancer, Recurrent Pancreatic Cancer, Acinar Cell Adenocarcinoma of the Pancreas.

What interventions are being tested in trial NCT01924260?

The interventions under investigation include: gemcitabine (DRUG), alisertib (DRUG).

Who is sponsoring clinical trial NCT01924260?

This trial is sponsored by Edward Kim, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01924260 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Unspecified Adult Solid Tumor, Protocol Specific

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Unspecified Adult Solid Tumor, Protocol Specific

All registered trials for this condition

Stage IV Pancreatic Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.